000166311 001__ 166311
000166311 005__ 20240229133519.0
000166311 0247_ $$2doi$$a10.1038/s41571-020-00447-z
000166311 0247_ $$2pmid$$apmid:33293629
000166311 0247_ $$2ISSN$$a1743-4254
000166311 0247_ $$2ISSN$$a1743-4262
000166311 0247_ $$2ISSN$$a1759-4774
000166311 0247_ $$2ISSN$$a1759-4782
000166311 0247_ $$2altmetric$$aaltmetric:95666753
000166311 037__ $$aDKFZ-2020-02804
000166311 041__ $$aeng
000166311 082__ $$a610
000166311 1001_ $$aWeller, Michael$$b0
000166311 245__ $$aEANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
000166311 260__ $$aNew York, NY$$bNature Publ. Group$$c2021
000166311 3367_ $$2DRIVER$$aarticle
000166311 3367_ $$2DataCite$$aOutput Types/Journal article
000166311 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1620221564_814$$xReview Article
000166311 3367_ $$2BibTeX$$aARTICLE
000166311 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166311 3367_ $$00$$2EndNote$$aJournal Article
000166311 500__ $$a#LA:B320#2021 Mar;18(3):170-186
000166311 520__ $$aIn response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of EANO provides recommendations for the diagnosis, treatment and follow-up of adult patients with diffuse gliomas. The diagnostic component is based on the 2016 update of the WHO Classification of Tumors of the Central Nervous System and the subsequent recommendations of the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy - Not Officially WHO (cIMPACT-NOW). With regard to therapy, we formulated recommendations based on the results from the latest practice-changing clinical trials and also provide guidance for neuropathological and neuroradiological assessment. In these guidelines, we define the role of the major treatment modalities of surgery, radiotherapy and systemic pharmacotherapy, covering current advances and cognizant that unnecessary interventions and expenses should be avoided. This document is intended to be a source of reference for professionals involved in the management of adult patients with diffuse gliomas, for patients and caregivers, and for health-care providers.
000166311 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000166311 588__ $$aDataset connected to CrossRef, PubMed,
000166311 7001_ $$00000-0001-5710-5127$$avan den Bent, Martin$$b1
000166311 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b2
000166311 7001_ $$aLe Rhun, Emilie$$b3
000166311 7001_ $$aTonn, Jörg C$$b4
000166311 7001_ $$00000-0003-1239-1603$$aMinniti, Giuseppe$$b5
000166311 7001_ $$aBendszus, Martin$$b6
000166311 7001_ $$00000-0003-0771-0390$$aBalana, Carmen$$b7
000166311 7001_ $$aChinot, Olivier$$b8
000166311 7001_ $$aDirven, Linda$$b9
000166311 7001_ $$00000-0002-0668-9529$$aFrench, Pim$$b10
000166311 7001_ $$00000-0003-0855-6495$$aHegi, Monika E$$b11
000166311 7001_ $$00000-0002-2860-9331$$aJakola, Asgeir S$$b12
000166311 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b13$$udkfz
000166311 7001_ $$aRoth, Patrick$$b14
000166311 7001_ $$aRudà, Roberta$$b15
000166311 7001_ $$00000-0003-4423-7256$$aShort, Susan$$b16
000166311 7001_ $$00000-0001-5563-2871$$aSmits, Marion$$b17
000166311 7001_ $$aTaphoorn, Martin J B$$b18
000166311 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b19$$udkfz
000166311 7001_ $$aWestphal, Manfred$$b20
000166311 7001_ $$00000-0002-9204-7038$$aSoffietti, Riccardo$$b21
000166311 7001_ $$0P:(DE-HGF)0$$aReifenberger, Guido$$b22
000166311 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b23$$eLast author$$udkfz
000166311 773__ $$0PERI:(DE-600)2491414-9$$a10.1038/s41571-020-00447-z$$n3$$p170-186$$tNature reviews / Clinical oncology$$v18$$x1759-4782$$y2021
000166311 909CO $$ooai:inrepo02.dkfz.de:166311$$pVDB
000166311 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000166311 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000166311 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000166311 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000166311 9130_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000166311 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000166311 9141_ $$y2021
000166311 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-09-04$$wger
000166311 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV CLIN ONCOL : 2018$$d2020-09-04
000166311 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-04
000166311 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-04
000166311 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-04
000166311 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-04
000166311 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-04
000166311 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-04
000166311 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-04
000166311 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bNAT REV CLIN ONCOL : 2018$$d2020-09-04
000166311 9201_ $$0I:(DE-He78)D170-20160331$$kD170$$lNeuroimmunologie und Hirntumorimmunologie$$x0
000166311 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000166311 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000166311 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK ED ES zentral$$x3
000166311 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x4
000166311 980__ $$ajournal
000166311 980__ $$aVDB
000166311 980__ $$aI:(DE-He78)D170-20160331
000166311 980__ $$aI:(DE-He78)HD01-20160331
000166311 980__ $$aI:(DE-He78)B300-20160331
000166311 980__ $$aI:(DE-He78)ED01-20160331
000166311 980__ $$aI:(DE-He78)B320-20160331
000166311 980__ $$aUNRESTRICTED